← Hutchmed (HCM) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Hutchmed (HCM)
Pharmaceutical Preparations · market cap $2.5B · as of 2026-07-17
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-23
Conference
Pipeline
12
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Hutchmed (HCM) is a ~$1.7B market cap pharmaceutical company with roughly 1,780 employees, operating a broad oncology pipeline spanning multiple Phase 2 and Phase 3 programs across hematologic malignancies and solid tumors. The lead catalyst is a Phase 3 trial of surufatinib combined with camrelizumab, nab-paclitaxel, and gemcitabine in metastatic pancreatic cancer, with the next scheduled event being a July 30, 2026 earnings release.
The catalyst path
- 2026-10-23Conferenceimp 4/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| HMPL-689 | Phase 2 | Relapsed/Refractory Lymphoma |
| Tazemetostat | Phase 2 | Relapsed/Refractory Follicular Lymphoma With EZH2 |
| Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine | Phase 3 | Metastatic Pancreatic Cancer |
| Surufatinib | Phase 2 | Neuroendocrine Tumors |
| HMPL-453 | Phase 3 | Advanced Intrahepatic Cholangiocarcinoma |
| Fruquintinib in Combination with Sintilimab | Phase 2 | Advanced Solid Tumor |
| Surufatinib in combination with Gemcitabine | Phase 2 | Solid Tumor |
| fruquintinib+sintilimab | Phase 3 | Advanced Renal Cell Carcinoma |
| HMPL-306 Regimen | Phase 3 | Acute Myeloid Leukemia |
| HMPL-760 planned dose 1 | Phase 2 | Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
| fruquintinib | Phase 3 | Advanced Endometrial Cancer |
| HMPL-A251 | Phase 2 | Solid Tumors, Adult |
Price & technical context
3-month
+22.1%
6-month
-7.8%
12-month
-10.9%
52-wk range
$9.99–$16.39
vs 50-day MA
+11.0%
vs 200-day MA
+7.6%
Realized vol
37.7%
Max drawdown
-53.2%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for HCM (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 12 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.